CapyFin

Calendar Reports Pricing

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Revolution Medicines (RVMD) Financial Analysis | CapyFin

Revolution Medicines

RVMD · NASDAQ🇺🇸

Earnings Dividends Seasonality Metrics

Reported earnings 28 days ago

Previous year: $15.3M

Previous year: -$0.63

Previous year: $66.1M

Previous year: $10.9M

Cash & Marketable Sec.

Previous year: $645M

Previous year: $12.7M

Cash and Equivalents

Previous year: $161M

Previous year: -$64.7M

Previous year: $812M

Loading...

Revolution Medicines

Unlock previous datapoints

Revolution Medicines

Unlock previous datapoints

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$19.1B

P/E Ratio

-17.80

Sector

N/A

Industry

N/A

52-Week High

$123

52-Week Low

$31

R&D Expenses

$148M

G&A Expenses

$32.2M

Cash & Marketable Sec.

$1.85B

Total Liabilities

$236M